Takeda Pharmaceutical Company Limited (TAK) News
Filter TAK News Items
TAK News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TAK News Highlights
- TAK's 30 day story count now stands at 52.
- Over the past 24 days, the trend for TAK's stories per day has been choppy and unclear. It has oscillated between 1 and 25.
- The most mentioned tickers in articles about TAK are DRUG, GENE and AG.
Latest TAK News From Around the Web
Below are the latest news stories about Takeda Pharmaceutical Co Ltd that investors may wish to consider to help them evaluate TAK as an investment opportunity.
Takeda Inks $2B Gene Therapy Pact With Code BiotherapeuticsTakeda Pharmaceutical Co Ltd (NYSE: TAK ) has signed up for a gene therapy pact, encoding a $2 billion biobucks deal with Code Biotherapeutics across four programs. The collaboration entails deploying Code''s non-viral gene therapies against liver-directed rare disease and central nervous system conditions. Through the agreement, Takeda and Code Bio will design and Full story available on Benzinga.com |
Real-World Analysis Show Takeda''s Alofisel Clinical Remission Rate At Six-MonthsTakeda Pharmaceutical Co Ltd (NYSE: TAK ) announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of Alofisel (darvadstrocel). The study demonstrated clinical remission in 65% of patients in both cohorts evaluated at six months, with Crohn''s disease … Full story available on Benzinga.com |
Takeda''s Alofisel shows remission in patients with Crohn’s diseaseTakeda Pharmaceutical (TAK) said an interim analysis in a post-approval study of Alofisel showed clinical remission at six months in 65% of patients with Crohn’s disease ((CD)) and… |
Real-World Analysis Show Takeda's Alofisel Clinical Remission Rate At Six-MonthsTakeda Pharmaceutical Co Ltd (NYSE: TAK) announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of Alofisel (darvadstrocel). The study demonstrated clinical remission in 65% of patients in both cohorts evaluated at six months, with Crohn's disease (CD) and complex perianal fistulas. Data were presented at the European Crohn's and Colitis Organisation (ECCO) 2022 Congress. Clinical response was observed in 73% (57/78) and 74% ( |
Alofisel®▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Real-World INSPIRE Study Interim Analysis Consistent with the Pivotal Clinical ADMIRE-CD Study1,2OSAKA, Japan & CAMBRIDGE, Massachusetts, February 18, 2022--Takeda (TSE:4502/NYSE:TAK) today announced the first six-month interim analysis results from INSPIRE, in which clinical remission* was observed in 65% of patients in both cohorts who were evaluated at 6 months.1 INSPIRE is a European, observational, multicenter, post-approval, open-enrollment study (EUPAS24267) evaluating the real-world effectiveness and safety of Alofisel (darvadstrocel) in patients with Crohn’s disease (CD) and comple |
The Best Russell 2000 Stocks to Buy Before they ReboundSome of the best stocks in the market are among the best Russell 2000 stocks to buy. |
Antibody Drug Conjugates (ADCs) Market Size to Reach USD 13.17 Billion by 2028 - Powered by Approval for Biologics License Applications – Vantage Market ResearchWASHINGTON, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Antibody Drug Conjugates (ADCS) Market finds that granted accelerated approval for biologics license applications is expediting market growth. Primarily driven by favourable effective biopharmaceutical medications developed as a targeted therapy for cancer therapy, the total global Antibody Drug Conjugates (ADCS) Market is estimated to reach USD 13.17 Billion by 2028. The Market valued at a revenue of USD 4.24 Billion in 2021, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 18.9%. Furthermore, the rising benefit of Antibody Drug Conjugates (ADCS) as the unharmed healthy cells enable patients to recover quickly, thus growth of the Global Antibody Drug Conjugates (ADCS... |
BioLife plasma donation facility joining Taylor Center in Arden-ArcadeA new medical facility that turns donated plasma into therapeutics is planning to join a retail center along Marconi Avenue in the Arden-Arcade area. |
10 Cheap Pharmaceutical Stocks For 2022In this article, we discuss 10 cheap pharmaceutical stocks for 2022. If you want to skip our detailed analysis of these stocks, go directly to 5 Cheap Pharmaceutical Stocks For 2022. The pharma industry is in the midst of a fundamental transformation as disruptive technologies like artificial intelligence, machine learning, and natural language processing become […] |
Ken Fisher Sold These 10 Stocks Before Entering 2022In this article, we discuss 10 stocks that Ken Fisher sold before entering 2022. If you want to skip our detailed analysis of these stocks, go directly to Ken Fisher Sold These 5 Stocks Before Entering 2022. Ken Fisher is the founder of Fisher Asset Management, an independent money manager headquartered in Washington. He stepped […] |